Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Explore how sexually transmitted infections progress, symptoms to watch for, and prevention strategies to protect sexual ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Accurate and ethical journalism on HIV/AIDS plays a vital role in shaping public perceptions, encouraging behavioral change, and raising awareness. Misinformation or vague reporting, however, can ...

SAN FRANCISCO -- At least 400 researchers, physicians, activists, and other concerned citizens gathered here Monday night to ...